Diffuse Large B-cell Lymphoma Therapeutics Market is expected to grow at a CAGR of 7.5% during the forecasting period 2021-2028

The global diffuse large b-cell lymphoma therapeutics market size was worth US$ 3,885.8 million in 2020 and is estimated to reach US$ YY million by 2028, growing at a CAGR of 7.5% during the forecast period (2021-2028). 

Diffuse large B-cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma (NHL). DLBCL is an aggressive (fast-growing) NHL that affects B-lymphocytes. Lymphocytes are one type of white blood cell. B-cells are lymphocytes that make antibodies to fight infections and are an important part of the lymphatic system.

Based on drug type, the global diffuse large b-cell lymphoma therapeutics market is broadly segmented as chemotherapy (cyclophosphamide (Cytoxan), doxorubicin (Adriamycin), vincristine (Oncovin), prednisone and Others), targeted therapy [Rituximab (Rituxan), Polatuzumab vedotin-piiq (Polivy), Tisagenlecleucel (Kymriah), Tafasitamab-cxix (Monjuvi), Selinexor (XPOVIO), Axicabtagene ciloleucel (Yescarta), Others (Pembrolizumab (Keytruda), Ibrutinib)] and Others (Combination).

Based on route of administration, the Diffuse Large B-cell Lymphoma Therapeutics Market is broadly segmented as intravenous route and oral route.

The intravenous route of administration segment is expected to witness the largest market revenue share in recent years and is expected to do so over the forecast period. This dominance is due to their rapid absorption and onset of action.

Based on end user, the global diffuse large b-cell lymphoma therapeutics market is broadly segmented as hospitals, clinics and others. Based on end user, hospitals account for the highest revenue in the market due to increased preference for the patients owing to the prevalence of hospital-associated cases in recent years. 

The North American region dominated the global diffuse large b-cell lymphoma therapeutics market in 2020 owing to the rising incidence of disease coupled with a high rate of mortality, demonstrates the unmet market need for better therapeutics. 

Market Dynamics

Drivers

• Increasing incidence of DLBCL (Diffuse Large B-Cell Lymphoma)
• Increasing preference for targeted therapies

Restraints

• High cost of treatment

Opportunities

• Patent cliffs of blockbuster drugs

Patent cliffs of blockbuster drugs

• Blockbuster drugs patent cliffs would offer lucrative opportunities for new entrants and established companies.
• Due to the patent expiration of the blockbuster drug Rituxan, multiple Rituxan Biosimilars have been developed and are available on the market, bolstering the diffuse large B-cell lymphoma industry.
• Rituxan has approximately five marketed biosimilars in Europe and three in the United States. Despite the availability of biosimilars, Rituxan sales are still on the rise. In the last three years, Rituxan has collected approximately US$ 32 billion in revenue.
• The huge market acceptance of Rituxan encourages the researchers and pharmaceutical industry to explore new opportunities in the drug

Geographical Analysis

Middle East & Africa diffuse large b-cell lymphoma therapeutics market is estimated to grow at a CAGR of 6.4% during the forecast period (2021-2028) to reach a market vale of USD YY million by 2028.

Developing health care infrastructure in countries in the Middle East & Africa is projected to accelerate the growth of the diffuse large b-cell lymphoma therapeutics market in the region. 

Middle East & Africa has a moderate growing market owing to the growing access and availability of medications for the treatment of diffuse large b-cell lymphoma  and rising social awareness regarding cancer treatment.

Although several reports examining the distribution of diffuse large b-cell lymphoma in the Middle East and in the Arab Gulf states in particular have been documented, no studies have been previously reported on the pattern of lymphoma in the UAE.

Several options are available in the Middle East for diffuse large b-cell lymphoma therapeutics such as chemotherapy, targeted therapy and some other therapies. Chemotherapy is the main way to treat most types of diffuse large b-cell lymphoma therapeutics. A combination of chemotherapy and the monoclonal antibody rituximab (Rituxan), with or without radiation therapy, can result in disease remission in a large number of patients with this form of lymphoma. Thus growing options of treatment and therapies in the region is driving the growth of the market in the forecast period.

Furthermore, increasing focus of manufacturers on adoption of inorganic growth strategies such as partnerships and acquisitions, in order to strengthen their product portfolio of relapsed or refractory diffuse large B-cell lymphoma which is anticipated to drive the market growth in the region.

About Us:

DataM Intelligence was incorporated in the early weeks of 2017 as a Market Research and Consulting firm with just two people on board. Within a span of less than a year, we have secured more than 100 unique customers from established organizations all over the world.

For more information:

Sai Kiran

Sales Manager at DataM Intelligence

Email: [email protected]

Tel: +1 877 441 4866

Website: www.datamintelligence.com